Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (<30 mg/dl) with rosuvastatin 20 mg daily (from jupiter)

American Journal of Cardiology

Volumn 114, Issue 11, 2014, Pages 1682-1689

  Everett, Brendan M ^a   Mora, Samia ^a   Glynn, Robert J ^a   Macfadyen, Jean ^a   Ridker, Paul M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; CREATINE KINASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; BILIARY TRACT DISEASE; BRAIN HEMORRHAGE; CHOLECYSTITIS; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; COMMON BILE DUCT STONE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DEPRESSION; DRUG SAFETY; FATIGUE; FATTY LIVER; FEMALE; GLOMERULUS FILTRATION RATE; HEMATURIA; HEPATOBILIARY DISEASE; HUMAN; INSOMNIA; KIDNEY DISEASE; KIDNEY FAILURE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENTAL DISEASE; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MYALGIA; MYOPATHY; MYOSITIS; NEOPLASM; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; POST HOC ANALYSIS; PROTEINURIA; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; SIDE EFFECT; URINARY TRACT DISEASE; BLOOD; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; LIVER DISEASES; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

AGED; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FLUOROBENZENES; HEMATURIA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER DISEASES; MALE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PYRIMIDINES; SLEEP INITIATION AND MAINTENANCE DISORDERS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84912127068     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2014.08.041     Document Type: Article

References (13)

1. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., J.J. Kastelein, W. Koenig, P. Libby, A.J. Lorenzatti, J.G. MacFadyen, B.G. Nordestgaard, J. Shepherd, J.T. Willerson, and R.J. Glynn Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
2. P.M. Ridker, A. Pradhan, J.G. MacFadyen, P. Libby, and R.J. Glynn Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial Lancet 380 2012 565 571
3. N.J. Stone, J.G. Robinson, A.H. Lichtenstein, C.N. Bairey Merz, C.B. Blum, R.H. Eckel, A.C. Goldberg, D. Gordon, D. Levy, D.M. Lloyd-Jones, P. McBride, J.S. Schwartz, S.T. Shero, S.C. Smith Jr., K. Watson, P.W. Wilson, K.M. Eddleman, N.M. Jarrett, K. LaBresh, L. Nevo, J. Wnek, J.L. Anderson, J.L. Halperin, N.M. Albert, B. Bozkurt, R.G. Brindis, L.H. Curtis, D. DeMets, J.S. Hochman, R.J. Kovacs, E.M. Ohman, S.J. Pressler, F.W. Sellke, W.K. Shen, S.C. Smith Jr., and G.F. Tomaselli 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 129 2014 S1 S45
4. J. Perk, G. De Backer, H. Gohlke, I. Graham, Z. Reiner, M. Verschuren, C. Albus, P. Benlian, G. Boysen, R. Cifkova, C. Deaton, S. Ebrahim, M. Fisher, G. Germano, R. Hobbs, A. Hoes, S. Karadeniz, A. Mezzani, E. Prescott, L. Ryden, M. Scherer, M. Syvanne, W.J. Scholte op Reimer, C. Vrints, D. Wood, J.L. Zamorano, F. Zannad European Association for Cardiovascular Prevention & Rehabilitation (EACPR) ESC Committee for Practice Guidelines (CPG) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Eur Heart J 33 2012 1635 1701
5. United States Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm. Accessed on August 13, 2014.
6. N. Sattar, D. Preiss, H.M. Murray, P. Welsh, B.M. Buckley, A.J. de Craen, S.R. Seshasai, J.J. McMurray, D.J. Freeman, J.W. Jukema, P.W. Macfarlane, C.J. Packard, D.J. Stott, R.G. Westendorp, J. Shepherd, B.R. Davis, S.L. Pressel, R. Marchioli, R.M. Marfisi, A.P. Maggioni, L. Tavazzi, G. Tognoni, J. Kjekshus, T.R. Pedersen, T.J. Cook, A.M. Gotto, M.B. Clearfield, J.R. Downs, H. Nakamura, Y. Ohashi, K. Mizuno, K.K. Ray, and I. Ford Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
7. D. Preiss, S.R. Seshasai, P. Welsh, S.A. Murphy, J.E. Ho, D.D. Waters, D.A. DeMicco, P. Barter, C.P. Cannon, M.S. Sabatine, E. Braunwald, J.J. Kastelein, J.A. de Lemos, M.A. Blazing, T.R. Pedersen, M.J. Tikkanen, N. Sattar, and K.K. Ray Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
8. S. Mora, J.D. Otvos, R.S. Rosenson, A. Pradhan, J.E. Buring, and P.M. Ridker Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women Diabetes 59 2010 1153 1160
9. A.D. Sniderman Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice J Clin Lipidol 2 2008 36 42
10. D.G. Vidt, P.M. Ridker, J.T. Monyak, M.J. Schreiber, and M.D. Cressman Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) Clin Ther 33 2011 717 725
11. J. Shepherd, J.J. Kastelein, V. Bittner, P. Deedwania, A. Breazna, S. Dobson, D.J. Wilson, A. Zuckerman, and N.K. Wenger Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study Clin J Am Soc Nephrol 2 2007 1131 1139
12. M. Tonelli, C. Isles, T. Craven, A. Tonkin, M.A. Pfeffer, J. Shepherd, F.M. Sacks, C. Furberg, S.M. Cobbe, J. Simes, M. West, C. Packard, and G.C. Curhan Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease Circulation 112 2005 171 178
13. K. Douglas, P.G. O'Malley, and J.L. Jackson Meta-analysis: the effect of statins on albuminuria Ann Intern Med 145 2006 117 124